Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital

Evolving Role of Biomarkers in SCLC

July 3rd 2023

Faculty discuss the evolving role of molecular markers in small-cell lung cancer and the need for future research to identify improved biomarkers for targeted treatment options.

Impact of Disease Staging on Prognosis and Treatment in SCLC

June 26th 2023

Panel experts review disease staging for limited and extensive stage small-cell lung cancer and discuss the impact of staging on treatment selection.

Q & A and Final Thoughts

August 20th 2020

Unmet Needs and Challenges in Treating R/R SCLC

August 20th 2020

Role of Newer Agents in the Treatment & Patient Selection

August 20th 2020

Data on FDA Approved Therapy for Relapsed/Refractory SCLC

August 20th 2020

Use of I/O Regimen in Relapsed/Refractory SCLC

August 20th 2020

Advice on Toxicity Management for SCLC Therapy

August 20th 2020

Personal Approach in Treatment Compared to Clinical Trials

August 20th 2020

Recent Progress in the Treatment of SCLC

August 20th 2020

Introduction and Identifying Predictive Biomarkers

August 20th 2020

Dr. Chiang on the Rationale for Chemoimmunotherapy in Lung Cancer

August 7th 2020

Anne Chiang, MD, PhD, discusses the rationale for combining immunotherapy with chemotherapy in lung cancer.

Dr. Chiang on Unanswered Questions With Immunotherapy in NSCLC

July 27th 2020

Anne Chiang, MD, PhD, discusses unanswered questions with immunotherapy in non–small cell lung cancer.

Dr. Chiang on Toxicities with Ipilimumab Plus Nivolumab in Small Cell Lung Cancer

September 1st 2017

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses the toxicities with ipilimumab (Yervoy) plus nivolumab (Opdivo) in small cell lung cancer (SCLC).

Dr. Chiang Discusses Ipilimumab Plus Nivolumab in Small Cell Lung Cancer

August 10th 2017

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses ipilimumab (Yervoy) plus nivolumab (Opdivo) in small cell lung cancer.

Dr. Chiang on Immunotherapy in Patient Populations for Lung Cancer

February 7th 2017

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses immunotherapy in specific patient populations with lung cancer.

Dr. Anne Chiang on Molecular Testing in Lung Cancer Treatment Planning

November 13th 2016

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses molecular testing in lung cancer and how it affects treatment decisions.